"Direct hit on the 'awakening switch' of the brain! ALKS.US's new drug for hypersomnia reports successful mid-term data. The Orexin track ignites the pharmaceutical competition."

Wisdom Finance app learned that at the sleep medicine annual meeting held in Baltimore on Wednesday, Alkermes (ALKS.US) announced that its experimental drug alixorexton significantly improved wakefulness maintenance in patients with type 2 narcolepsy and reduced excessive daytime sleepiness. This finding suggests that the highly anticipated orexin receptor agonist class of new drugs may benefit a wider range of patients than originally expected.